Rycarma Therapeutics Inc.
- Address
- 200 Clarendon Street
Sponsor Overview
Specializations
Neuromuscular Disease
Rycarma Therapeutics Inc. focuses on autosomal dominant RYR1-related myopathy, with interest in muscle function, weakness, and fatigability in adult patients. The clinical programme includes evaluation of skeletal muscle performance and related functional outcomes.
- Muscle strength
- Fatigability
- Functional mobility
The research activity includes assessment of treatment effects on day-to-day physical performance in a rare inherited myopathy.
Cardiac Rhythm Disorders
The sponsor also has interest in cardiac arrhythmias, reflecting involvement in disorders of heart rhythm and electrical stability. This area aligns with therapeutic work targeting abnormal cardiac conduction and rhythm control.
- Heart rhythm abnormalities
- Cardiac electrical activity
- Rhythm-related safety
This therapeutic domain supports clinical evaluation of agents intended to address rhythm disturbances in cardiovascular disease.
Muscle Function Assessment
Clinical research activity includes endpoints centered on muscle performance, with attention to strength, endurance, and physical exertion tolerance. Functional testing is used to capture changes in mobility and overall neuromuscular capacity.
- 1-minute sit-to-stand test
- Physical endurance
- Exercise tolerance
These measures are relevant to disorders where impaired muscle activation limits daily activity and independence.
Therapeutic Safety and Tolerability
The sponsor’s trials also examine safety, tolerability, and pharmacokinetics in relation to investigational therapy development. This area supports clinical work in both healthy volunteers and patients with inherited muscle disease.
- Safety monitoring
- Tolerability evaluation
- Pharmacokinetic profiling
These studies are part of the sponsor’s interest in advancing therapies for rare neuromuscular disorders and related cardiac conditions.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Surlorian in Adults with Autosomal Dominant RYR1-Related Myopathy: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial |  France Germany Spain The Netherlands | Recruiting |
| Safety, Tolerability, and Pharmacokinetics of ARM210 in Cardiac Arrhythmias: A Randomized, Placebo-Controlled Study in Healthy Subjects | The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 8 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
Partnered Research Centres
8 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Pasealeku Doct. Begiristain 109, 20014 Donostia / San Sebastian
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona
- Address
- Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Rycarma Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.